8-K: Absci Reports Business Updates and Full Year 2023 Financial Results, Secures AstraZeneca Collaboration and $86M Capital Raise

Absci announced its fourth quarter and full year 2023 financial results, highlighted by a new collaboration with AstraZeneca, progress in its internal pipeline, and a successful $86 million capital raise.

Summary

• Absci reported its financial results for the fourth quarter and full year ended December 31, 2023.
• The company initiated IND-enabling studies for ABS-101, a potential best-in-class anti-TL1A antibody.
• Absci entered into a collaboration with AstraZeneca for up to $247 million in deal value, plus royalties.
• They strengthened their balance sheet by raising approximately $86 million through an underwritten common stock offering.
• Revenue for the full year 2023 was $5.7 million, consistent with 2022.
• Research and development expenses for the full year 2023 were $48.1 million, down from $58.9 million in 2022.
• The net loss for the full year 2023 was $110.6 million, compared to $104.9 million in 2022.
• Absci believes its current cash and investments will fund operations into the first half of 2027.
• The company expects a gross use of cash of approximately $80 million for the fiscal year ending December 31, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with significant progress in partnerships and pipeline development, along with a successful capital raise. However, the company is still experiencing losses and is dependent on future success.

Positives

• The collaboration with AstraZeneca provides significant potential revenue through upfront payments, research funding, milestone payments, and royalties.
• The successful $86 million capital raise strengthens the company's financial position.
• Absci is making progress on its internal pipeline with ABS-101 moving into IND-enabling studies.
• The company has reduced research and development expenses year-over-year.
• Absci has a cash runway into the first half of 2027, providing financial stability.
• The company is actively pursuing multiple drug creation partnerships.

Negatives

• Revenue for the fourth quarter of 2023 decreased to $0.3 million from $1.6 million in the same period of 2022.
• The net loss for the full year 2023 was $110.6 million, an increase from $104.9 million in 2022.
• The company is still experiencing significant operating losses.
• Selling, general, and administrative expenses increased in the fourth quarter of 2023 compared to the same period in 2022.

Risks

• The company's success is dependent on the successful development and commercialization of its drug candidates.
• Clinical trials may not replicate positive preclinical results.
• Absci relies on third parties for manufacturing and supply of its product candidates.
• The company's partnerships may not be successful or may not generate the expected revenue.
• Regulatory approvals are not guaranteed and can be delayed.
• The company's financial performance is subject to market conditions and regulatory developments.

Future Outlook

Absci believes its existing cash and investments will be sufficient to fund its operations into the first half of 2027. The company anticipates signing additional drug creation partnerships and advancing its internal pipeline programs.

Management Comments

• In 2023, Absci further solidified its leadership in AI-driven biologic drug discovery, said Sean McClain, Founder and CEO.
• Our breakthroughs in generative AI drug creation have rapidly translated into a differentiated internal portfolio of potential best-in-class and first-in-class programs.
• With validating strategic industry partnerships and our recent underwritten public offering, we're poised to further advance our pipeline, enhance our AI capabilities, and expand our partnerships.
• These efforts reflect our commitment to innovation, promising better biologics for patients, faster.

Industry Context

The announcement highlights Absci's position in the competitive AI-driven drug discovery space. The collaboration with AstraZeneca, a major pharmaceutical company, validates Absci's technology and approach. The focus on internal pipeline development and partnerships aligns with industry trends in biotechnology.

Comparison to Industry Standards

• Absci's collaboration with AstraZeneca is similar to other biotech companies partnering with large pharmaceutical firms for drug development, such as BioNTech's partnership with Pfizer for mRNA vaccines.
• The $247 million potential deal value with AstraZeneca is comparable to other early-stage biotech deals, but the actual revenue will depend on achieving milestones and royalties.
• The company's focus on AI-driven drug discovery is in line with the growing trend of using artificial intelligence to accelerate drug development, similar to companies like Recursion Pharmaceuticals and Exscientia.
• Absci's cash runway into the first half of 2027 is a positive sign, but it is important to compare this to other biotech companies of similar size and stage, such as those in the XBI ETF, which have varying cash positions and burn rates.
• The company's net loss of $110.6 million for 2023 is typical for a pre-revenue biotech company, but it is important to monitor the burn rate and progress towards commercialization.

Management Changes

Stakeholder Impact

• Shareholders benefit from the strengthened financial position and potential for future growth.
• Employees are likely to see continued investment in the company and its programs.
• Customers and partners may see increased collaboration opportunities and potential for new therapies.
• Suppliers and creditors may see increased business opportunities with Absci.

Next Steps

• Absci will continue IND-enabling studies for ABS-101.
• The company expects to submit an IND for ABS-101 in the first quarter of 2025.
• Absci will select a development candidate for ABS-201 in the second half of 2024.
• Mode-of-action validation studies for ABS-301 will be completed in the second half of 2024.
• Absci plans to sign additional drug creation partnerships in 2024.
• The company will continue to advance its internal pipeline programs.

Key Dates

Keywords

AI drug discovery, biologics, antibody, generative AI, AstraZeneca, IND-enabling studies, clinical trials, capital raise, partnerships, oncology, dermatology, immunology